Neurocrine Biosciences ((NBIX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurocrine Biosciences is conducting a study titled A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE). The study aims to assess the safety and tolerability of the drug NBI-921352 when used alongside other treatments for patients with SCN8A-DEE, a rare and severe neurological disorder.
The intervention being tested is NBI-921352, an experimental drug administered orally. It is designed to be used as an additional therapy for managing symptoms associated with SCN8A-DEE.
This interventional study follows a single-group model without masking, focusing on treatment as its primary purpose. Participants receive the drug for up to 164 weeks to evaluate its long-term safety and tolerability.
The study began on July 12, 2022, and is currently active but not recruiting new participants. The last update was submitted on July 14, 2025, indicating ongoing progress in the study.
The outcome of this study could significantly impact Neurocrine Biosciences’ stock performance and investor sentiment, particularly if the results demonstrate positive safety and tolerability. In the competitive landscape of neurological disorder treatments, successful results could position Neurocrine as a leader in this niche market.
The study is ongoing, with further details available on the ClinicalTrials portal.